At Amryt Pharma, we look beyond the ordinary, unearthing scientific potential and delivering medicines that may or have the potential to change the lives of people with rare, debilitating conditions.
Through our in-depth knowledge and bold approach, we combine the expertise and innovation needed to help patients and their caregivers to access new treatments quickly and responsibly.
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a growing commercial business and a significant development pipeline.
A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders we create a clear path for our transformative medicines to reach those that need them.
At Amryt Pharma we have an exceptional team with the collective vision to deliver medicines that are truly transformative for people with rare, debilitating illnesses.
Our leadership team offers a wealth of experience in identifying, commercialising and delivering new treatments across global markets. Our ability to navigate diverse regulatory and reimbursement environments, combining a ‘think global, act local approach’, positions us optimally to deliver our goals.
Amryt Pharma Plc
Dept 920A
196 High Road, Wood Green
London, N22 8HH
Tel: +44 20 3026 7257
Aegerion Pharmaceuticals Inc.
(A wholly owned subsidiary of Amryt Pharmaceuticals)
Satellite Office,
53 State Street, Suite 500
Boston, MA 02109
USA
Tel: +1 617 500 7867
Amryt GmBH
Streiflingsweg 11
75223 Niefern-Oschelbronn
Germany
Tel: +49 7233 97490
Aegerion Pharmaceuticals Inc.
(A wholly owned subsidiary of Amryt Pharmaceuticals)
US Headquarters,
245 First Street, 18th Floor,
Cambridge, MA 02142,
USA
Tel: +1 617.500.7867
